	Frais De Vente Et D'Administration		Date
AbbVie	USD 3.89B	325M	2025-12
Acadia Pharmaceuticals	USD 124.9M	1.24M	2025-09
ALKERMES	USD 171.77M	17.9M	2025-09
Amgen	USD 1.94B	237M	2025-12
Bayer	EUR 3.4B	140M	2025-09
Biogen	USD 545.2M	38.6M	2025-09
BioMarin Pharmaceutical	USD 223.42M	8.86M	2025-09
Bristol-Myers Squibb	USD 2.18B	392M	2025-12
Eli Lilly	USD 3.13B	391.3M	2025-12
Esperion Therapeutics	USD 39.98M	4.21M	2024-09
Gilead Sciences	USD 1.78B	425M	2025-12
Incyte	USD 390.41M	61.33M	2025-12
Merck	USD 2.85B	215M	2025-12
Moderna	USD 308M	40M	2025-12
Neurocrine Biosciences	USD 301.8M	10.2M	2025-12
Novartis	USD 3.31B	134M	2025-09
Pfizer	USD 4.08B	894M	2025-12
PTC Therapeutics	USD 87.2M	3.15M	2025-12
Puma Biotechnology	USD 16.82M	8.15M	2024-09
Regeneron Pharmaceuticals	USD 775M	117.2M	2025-12
Sangamo BioSciences	USD 9.64M	1.83M	2024-06
Sanofi	EUR 2.75B	455M	2025-12
Sanofi	EUR 2.75B	455M	2025-12
Sarepta Therapeutics	USD 77.11M	7.22M	2025-09
Teva Pharmaceutical Industries	USD 1.12B	147M	2025-12
Ultragenyx Pharmaceutical	USD 89M	2.38M	2025-12
United Therapeutics	USD 152M	60.5M	2025-09
Vertex Pharmaceuticals	USD 487M	41.9M	2025-12

Biogen Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.